Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma

Tian, Nan; Shangguan, Wenbing; Zhou, Zuolin; yao, Yao; Fan, Cheng; Cai, Lijun

doi:10.7150/jca.33421

Cited by 30 publications

(12 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nuclear factor-kappaB (NF-κB) is suggested to be involved in mediating paclitaxel resistance in hepatocellular carcinoma (HCC) via upregulating Lin28B. Curcumin administration (5, 10 and 20 μM) leads to suppressing NF-κB-mediated Lin28B and preventing paclitaxel resistance in HCC cells [ 63 ]. It is worth mentioning that curcumin is capable of affecting drug transporters in enhancing sensitivity of cancer cells to paclitaxel chemotherapy.…”

Section: Curcumin In Cancer Chemotherapy: Beyond Doxorubicinmentioning

confidence: 99%

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

et al. 2020

View full text Add to dashboard Cite

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field of cancer therapy. However, similar to other chemotherapeutic agents such as cisplatin, paclitaxel, docetaxel, etoposide and oxaliplatin, cancer cells are able to obtain chemoresistance that limits DOX efficacy. In respect to dose-dependent side effect of DOX, enhancing its dosage is not recommended for effective cancer chemotherapy. Therefore, different strategies have been considered for reversing DOX resistance and diminishing its side effects. Phytochemical are potential candidates in this case due to their great pharmacological activities. Curcumin is a potential antitumor phytochemical isolated from Curcuma longa with capacity of suppressing cancer metastasis and proliferation and affecting molecular pathways. Experiments have demonstrated the potential of curcumin for inhibiting chemoresistance by downregulating oncogene pathways such as MMP-2, TGF-β, EMT, PI3K/Akt, NF-κB and AP-1. Furthermore, coadministration of curcumin and DOX potentiates apoptosis induction in cancer cells. In light of this, nanoplatforms have been employed for codelivery of curcumin and DOX. This results in promoting the bioavailability and internalization of the aforementioned active compounds in cancer cells and, consequently, enhancing their antitumor activity. Noteworthy, curcumin has been applied for reducing adverse effects of DOX on normal cells and tissues via reducing inflammation, oxidative stress and apoptosis. The current review highlights the anticancer mechanism, side effects and codelivery of curcumin and DOX via nanovehicles.

show abstract

Section: Curcumin In Cancer Chemotherapy: Beyond Doxorubicinmentioning

confidence: 99%

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…LIN28B is a well-known cancer promotor and had been characterized recently to be associated with drug response in HCC [ 46 ]. Moreover, LIN28B was upregulated in HCC tissues, and high LIN28B expression was a ssociated with high α-fetoprotein levels and shorter overall survival in HCC patients [ 47 ]. Furthermore, LIN28B was described to be a tumor marker and to be associated with tumor recurrence in HCC[ [48] , [49] , [50] ].…”

Section: Discussionmentioning

confidence: 99%

Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11

et al. 2021

View full text Add to dashboard Cite

The poor prognosis of advanced hepatocellular carcinoma (HCC) is driven by diverse features including dysregulated microRNAs inducing drug resistance and stemness. Lin-28 homolog A (LIN28A) and its partner zinc finger CCHC-type containing 11 (ZCCHC11) cooperate in binding, oligouridylation and subsequent degradation of tumorsuppressive let-7 precursor microRNAs. Functionally, activation of LIN28A was recently shown to promote stemness and chemoresistance in HCC. However, the expression and regulation of LIN28A in HCC had been unclear. Moreover, the expression, regulation and function of ZCCHC11 in liver cancer remained elusive. In contrast to "one-microRNA-one-target" interactions, we identified common binding sites for miR-622 in both LIN28A and ZCCHC11, suggesting miR-622 to function as a superior pathway regulator. Applying comprehensive microRNA database screening, human hepatocytes and HCC cell lines, patient-derived tissue samples as well as "The Cancer Genome Atlas" (TCGA) patient cohorts, we demonstrated that loss of tumorsuppressive miR-622 mediates derepression and overexpression of LIN28A in HCC. Moreover, the cooperator of LIN28A, ZCCHC11, was newly identified as a prognostic and therapeutic target of miR-622 in liver cancer. Together, identification of novel miR-622 target genes revealed common regulation of cooperating genes and outlines the previously unknown oncogenic role of ZCCHC11 in liver cancer.

show abstract

“…LIN28B is highly expressed in liver cells and is related to the level of alpha-fetoprotein, which promotes the tumorigenesis and progression of HCC. The overall survival rate of HCC patients with high LIN28B expression in signi cantly shortened, which is related to the multidrug resistance of HCC [41] . SMG5 is highly expressed in malignant tumors, especially prostate cancer and it is a potential molecular marker for the early diagnosis of cancers [42] .…”

Section: Discussionmentioning

confidence: 99%

Systematic Analysis of the Function and Prognostic Value of RNA-Binding Proteins in Hepatocellular Carcinoma

Wu¹,

Yang²,

Yang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: RNA-binding proteins (RBPs) are abnormally expressed in a variety of malignant tumors and are closely related to tumorigenesis, tumor progression, and prognosis. The role of RBPs in hepatocellular carcinoma (HCC) is unclear. Based on the cancer genome atlas (TCGA) database, we conducted a systematic bioinformatics analysis of abnormally expressed RBPs in HCC, with the aim of identifying the prognostic markers and potential therapeutic targets.Methods: HCC RNA sequencing data downloaded from TCGA database were used to determine the differentially expressed RBPs in livery cancer and normal tissues, followed by performing functional enrichment analysis and visualization of interaction relationships. Univariate and multivariate Cox regression analyses were subsequently used to identify RBPs that were significantly related to the prognosis to construct a prognostic model. The predictive performance of the prognostic model was evaluated by survival analysis and receiver operating characteristic (ROC) curve analysis and verified in the test cohort. Human protein atlas online database was used to verify the expression level of RBPs in the prognostic model.Results: In total, 82 differentially expressed RBPs were identified, including 55 upregulated and 27 downregulated RBPs. Further functional enrichment and interaction analyses showed that the differentially expressed RBPs were mainly related to regulating of mRNA metabolic process, RNA catabolic, mRNA catabolic process, and macromolecule methylation. Five RBP genes, LIN28B, SMG5, PPARGC1A, LARP1B, and ANG were identified as prognostic-related genes and used to construct the prognostic model. The predictive ability of the prognostic model was verified in the test cohort. ROC curve analysis showed that the prognostic model had good sensitivity and specificity. Independent prognostic analysis showed that the risk score may be an independent prognostic factor for HCC.Conclusion: This study constructed a reliable prognostic prediction model by analyzing the differentially expressed RBPs of HCC, facilitating the identification of HCC prognostic biomarkers and therapeutic targets.

show abstract

Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma

Cited by 30 publications

References 50 publications

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11

Systematic Analysis of the Function and Prognostic Value of RNA-Binding Proteins in Hepatocellular Carcinoma

Contact Info

Product

Resources

About